Vol – 2 | Issue – 1 | Jan – 2024
- Pradhan B,1 Barik H.2
- GAS Journal of Clinical Medicine and Medical Research. Published by GAS Publishers
- GAS Journal of Clinical Medicine and Medical Research (GASJCMMR)
Abstract: There is accumulating emerging evidences on the extended therapeutic potential of antimalarial drugs, particularly artemisinin derivatives have anti-SARS-CoV-2(COVID-19) effects. The artemisinin derivative Artesunate and Artemether have most promising agents exhibiting improved pharmacokinetic properties and have pleotropic effects. Artemisinin-based combination therapy (ACT) at recommended doses clinically used in malaria, showed in-vitro inhibition of SARS-CoV-2 replication and ACTs containing Artemether/Artesunate in combination with Lumefantrine/Mefloquine/Amodiaquine would be attractive candidates for treatment of COVID-19 considering their excellent safety profiles in humans and available at a relatively low cost.
Keywords: SARS-CoV-2, COVID-19, ACT, Artesunate, Artemether, Lumefantrine, Amodiaquine.
